764 related articles for article (PubMed ID: 25875942)
1. LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD).
Soares e Silva AK; de Oliveira Cipriano Torres D; dos Santos Gomes FO; dos Santos Silva B; Lima Ribeiro E; Costa Oliveira A; dos Santos LA; de Lima Mdo C; Pitta Ida R; Peixoto CA
PLoS One; 2015; 10(4):e0123787. PubMed ID: 25875942
[TBL] [Abstract][Full Text] [Related]
2. Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD).
Araújo S; Soares E Silva A; Gomes F; Ribeiro E; Oliveira W; Oliveira A; Lima I; Lima MDC; Pitta I; Peixoto C
Eur J Pharmacol; 2016 Oct; 788():306-314. PubMed ID: 27349145
[TBL] [Abstract][Full Text] [Related]
3. Effect of new thiazolidine derivatives LPSF/GQ-02 and LPSF/GQ-16 on atherosclerotic lesions in LDL receptor-deficient mice (LDLR(-/-)).
Soares E Silva AK; de Oliveira Cipriano Torres D; Santos Rocha SW; dos Santos Gomes FO; dos Santos Silva B; Donato MA; Raposo C; Santos AC; de Lima Mdo C; Galdino SL; da Rocha Pitta I; de Souza JR; Peixoto CA
Cardiovasc Pathol; 2013; 22(1):81-90. PubMed ID: 22795892
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure.
Zaitone SA; Barakat BM; Bilasy SE; Fawzy MS; Abdelaziz EZ; Farag NE
Naunyn Schmiedebergs Arch Pharmacol; 2015 Jun; 388(6):587-600. PubMed ID: 25708949
[TBL] [Abstract][Full Text] [Related]
5. Chronic LPSF/GQ-02 treatment attenuates inflammation and atherosclerosis development in LDLr
Silva AKSE; Gomes FODS; Santos Silva BD; Ribeiro EL; Oliveira AC; Araújo SMDR; de Lima IT; Oliveira AGV; Rudnicki M; Abdalla DSP; Lima MDCA; Pitta IDR; Peixoto CA
Eur J Pharmacol; 2016 Nov; 791():622-631. PubMed ID: 27693798
[TBL] [Abstract][Full Text] [Related]
6. Ameliorative effect of nicorandil on high fat diet induced non-alcoholic fatty liver disease in rats.
Elshazly SM
Eur J Pharmacol; 2015 Feb; 748():123-32. PubMed ID: 25542756
[TBL] [Abstract][Full Text] [Related]
7. Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model.
Nozaki Y; Fujita K; Wada K; Yoneda M; Kessoku T; Shinohara Y; Imajo K; Ogawa Y; Nakamuta M; Saito S; Masaki N; Nagashima Y; Terauchi Y; Nakajima A
BMC Gastroenterol; 2015 Apr; 15():42. PubMed ID: 25881230
[TBL] [Abstract][Full Text] [Related]
8. Protective effect and mechanism of Qiwei Tiexie capsule on 3T3-L1 adipocytes cells and rats with nonalcoholic fatty liver disease by regulating LXRα, PPARγ, and NF-κB-iNOS-NO signaling pathways.
Suolang PC; Liu BQ; Chen J; De J; Nima ZB; Dunzhu CR
J Ethnopharmacol; 2019 May; 236():316-325. PubMed ID: 30851372
[TBL] [Abstract][Full Text] [Related]
9. Long-term subcutaneous injection of lipopolysaccharides and high-fat diet induced non-alcoholic fatty liver disease through IKKε/ NF-κB signaling.
He Q; Zeng J; Yao K; Wang W; Wu Q; Tang R; Xia X; Zou X
Biochem Biophys Res Commun; 2020 Nov; 532(3):362-369. PubMed ID: 32883523
[TBL] [Abstract][Full Text] [Related]
10. Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine N-methyltransferase-deficient mice.
van der Veen JN; Lingrell S; Gao X; Quiroga AD; Takawale A; Armstrong EA; Yager JY; Kassiri Z; Lehner R; Vance DE; Jacobs RL
Am J Physiol Gastrointest Liver Physiol; 2016 Apr; 310(7):G526-38. PubMed ID: 26797396
[TBL] [Abstract][Full Text] [Related]
11. Nicotinic acetylcholine receptor α7 subunit improves energy homeostasis and inhibits inflammation in nonalcoholic fatty liver disease.
Li DJ; Liu J; Hua X; Fu H; Huang F; Fei YB; Lu WJ; Shen FM; Wang P
Metabolism; 2018 Feb; 79():52-63. PubMed ID: 29129819
[TBL] [Abstract][Full Text] [Related]
12. Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distribution.
Nozaki Y; Fujita K; Wada K; Yoneda M; Shinohara Y; Imajo K; Ogawa Y; Kessoku T; Nakamuta M; Saito S; Masaki N; Nagashima Y; Terauchi Y; Nakajima A
BMC Gastroenterol; 2015 Dec; 15():177. PubMed ID: 26678309
[TBL] [Abstract][Full Text] [Related]
13. Combined treatments with metformin and phosphodiesterase inhibitors alleviate nonalcoholic fatty liver disease in high-fat diet fed rats: a comparative study.
Heeba GH; El-Deen RM; Abdel-Latif RG; Khalifa MMA
Can J Physiol Pharmacol; 2020 Aug; 98(8):498-505. PubMed ID: 32083947
[TBL] [Abstract][Full Text] [Related]
14. Nimesulide, a cyclooxygenase-2 selective inhibitor, suppresses obesity-related non-alcoholic fatty liver disease and hepatic insulin resistance through the regulation of peroxisome proliferator-activated receptor γ.
Tsujimoto S; Kishina M; Koda M; Yamamoto Y; Tanaka K; Harada Y; Yoshida A; Hisatome I
Int J Mol Med; 2016 Sep; 38(3):721-8. PubMed ID: 27431935
[TBL] [Abstract][Full Text] [Related]
15. SARM1 deletion restrains NAFLD induced by high fat diet (HFD) through reducing inflammation, oxidative stress and lipid accumulation.
Pan ZG; An XS
Biochem Biophys Res Commun; 2018 Apr; 498(3):416-423. PubMed ID: 29454967
[TBL] [Abstract][Full Text] [Related]
16. Li-Gan-Shi-Liu-Ba-Wei-San improves non-alcoholic fatty liver disease through enhancing lipid oxidation and alleviating oxidation stress.
Jiang Y; Chen L; Wang H; Narisi B; Chen B
J Ethnopharmacol; 2015 Dec; 176():499-507. PubMed ID: 26571089
[TBL] [Abstract][Full Text] [Related]
17. The effects of perfluorooctanoate on high fat diet induced non-alcoholic fatty liver disease in mice.
Li X; Wang Z; Klaunig JE
Toxicology; 2019 Mar; 416():1-14. PubMed ID: 30711707
[TBL] [Abstract][Full Text] [Related]
18. Effects of Chinese Medicinal Formula BNG-1 on Phosphodiesterase 3B Expression, Hepatic Steatosis, and Insulin Resistance in High Fat Diet-induced NAFLD Mice.
Guo CH; Chen WL; Liao CH; Huang K; Chen PY; Yang CP
Int J Med Sci; 2018; 15(11):1194-1202. PubMed ID: 30123057
[No Abstract] [Full Text] [Related]
19. NLRP3 inhibitor glibenclamide attenuates high-fat diet and streptozotocin-induced non-alcoholic fatty liver disease in rat: studies on oxidative stress, inflammation, DNA damage and insulin signalling pathway.
Dwivedi DK; Jena GB
Naunyn Schmiedebergs Arch Pharmacol; 2020 Apr; 393(4):705-716. PubMed ID: 31834465
[TBL] [Abstract][Full Text] [Related]
20. (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation.
Park EJ; Kim YM; Kim HJ; Jang SY; Oh MH; Lee DH; Chang KC
Eur J Pharmacol; 2016 Oct; 788():200-209. PubMed ID: 27343380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
